A nurse is caring for a patient with chronic obstructive pulmonary disease (COPD) who has been prescribed a combination inhaler containing a long acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS). Which therapeutic effect should the nurse expect from this medication?

A. Reduction in frequency of COPD exacerbations: The combination of a long-acting beta2-agonist and an inhaled corticosteroid helps relax airway smooth muscles and reduce airway inflammation. This dual action improves airflow, decreases symptoms such as dyspnea, and lowers the risk and frequency of COPD exacerbations, enhancing disease management. B. Exacerbation of inflammation and bronchoconstriction: Inhaled corticosteroids and LABAs work to decrease inflammation and promote bronchodilation. They do not worsen airway inflammation or constriction; rather, they improve respiratory function and symptom control. C. Cure of underlying COPD pathology: COPD is a chronic, progressive disease with irreversible structural changes in the lungs. Medications like LABA/ICS improve symptoms and reduce exacerbations but do not cure the underlying pathology. D. Prevention of pneumonia: While inhaled corticosteroids may slightly increase the risk of pneumonia in some COPD patients, the combination therapy is not intended to prevent infections. Its primary goal is symptom control and reduction of exacerbations.